Within the SEL24 project Selvita is exploring the potential of targeting two critical kinases, namely PIM and FLT3 mutants, shown to be crucial for development of acute myeloid leukemia and pursued by our competitors using target-selective inhibitors. We have developed the first in class molecule targeting mutated forms of FLT3 and downstream effectors of FLT3 signaling, namely the family of PIM kinases. Our dual-activity, clinical candidate molecule, SEL24-B489 shows superior activity on a panel of AML models, both in vitro and in vivo in comparison to selective inhibitors, excellent bioavailability and promising initial toxicology profile. On top of these data, observed synergism with cytarabine further increases the chances of success of our drug in clinical trials. Clinical development of the program is planned for 2015.